Pharmaceuticals News and Research

RSS

Johns Hopkins trained physicians create start-up to produce cheap generic drugs

A group of Johns Hopkins trained physicians has started a crowdfunding campaign to create a start-up which produces cheap generic drugs.

23 Sep 2015

OncoGenex reports results from Phase 2 Rainier study in patients with untreated metastatic pancreatic cancer

OncoGenex Pharmaceuticals, Inc. announced today initial results from the Phase 2 Rainier study evaluating apatorsen in combination with ABRAXANE (paclitaxel protein-bound particles for injectable suspension) (albumin-bound) and gemcitabine compared to ABRAXANE and gemcitabine alone in patients with untreated metastatic pancreatic cancer.

23 Sep 2015

Novel graphene oxide-based biosensor may speed up development of new drugs against HIV, cancer

Longing to find a cure for cancer, HIV and other yet incurable diseases, researchers have already tried out hundreds of drugs, each requiring preclinical and clinical testing with live subjects. How many chemical agents more to try? Moving at such rate, will we find the cure during our lifetime? One of the easiest ways to speed up the drug development process is to simply perform it outside of the living body (e.g., by watching the substances react with the smallest pieces of live tissue and thus quickly predicting the overall effect it will make to the body when inside).

23 Sep 2015

NJIT President Joel Bloom to be honored as Educator of the Year

The Research & Development Council of New Jersey will honor the winners of the 2015 Edison Patent Awards at the 36th Edison Patent Awards Ceremony & Reception on November 12, 2015. Over 50 inventors and 12 New Jersey companies and universities will be recognized at the event.

23 Sep 2015

Drug combination delivers effective punch against one form of pancreatic cancer

One form of pancreatic cancer has a new enemy: a two-drug combination discovered by UF Health researchers that inhibits tumors and kills cancer cells in mouse models.

22 Sep 2015

FDA approves LONSURF for treatment of patients with metastatic colorectal cancer

Taiho Oncology, Inc. (U.S.), a subsidiary of Taiho Pharmaceutical Co., Ltd. (Japan), today announced that the U.S. Food and Drug Administration approved LONSURF (trifluridine and tipiracil), formerly known as TAS-102, for the treatment of patients with metastatic colorectal cancer (mCRC) who have been previously treated with fluoropyrimidine-, oxaliplatin- and irinotecan-based chemotherapy, an anti-VEGF biological therapy, and if RAS wild-type, an anti-EGFR therapy.

22 Sep 2015

Type 2 diabetes risk grows with active and passive smoking

A meta-analysis of 88 studies covering nearly 6 million people published in The Lancet Diabetes & Endocrinology shows that both active and passive smoking are linked to increased risk of type 2 diabetes, while the risk in those who quit smoking decreases as time elapses since their last cigarette.

22 Sep 2015

BWH, DFCI researchers receive $10 million to test effectiveness of aspirin in women with breast cancer

Researchers from Brigham and Women's Hospital and Dana-Farber Cancer Institute have received a $10 million Breakthrough Award from the Department of Defense's Office of the Congressionally Directed Medical Research Program to test whether aspirin helps women with breast cancer avoid recurrence and live longer.

22 Sep 2015

PDL BioPharma purchases portion of royalties on expected sales of AcelRx's Zalviso

PDL BioPharma, Inc. announced today that it has acquired a portion of the royalties on expected sales of AcelRx Pharmaceuticals Inc.'s Zalviso (sufentanil sublingual tablet system) in the European Union, Switzerland and Australia by its commercial partner, Grunenthal.

21 Sep 2015

Palatin Technologies reports net loss of $12.1 million for fourth quarter 2015

Palatin Technologies, Inc., a biopharmaceutical company developing targeted, receptor-specific peptide therapeutics for the treatment of diseases with significant unmet medical need and commercial potential, today announced results for its fourth quarter and fiscal year ended June 30, 2015.

21 Sep 2015

New Locilex microbiology data presented at ICAAC/ICC 2015 scientific conference

Dipexium Pharmaceuticals, Inc., a late-stage pharmaceutical company focused on the development and commercialization of Locilex (pexiganan cream 0.8%), and research collaborators, JMI Laboratories, announced that new Locilex microbiology data were presented at the American Society for Microbiology's Interscience Conference of Antimicrobial Agents and Chemotherapy and International Society of Chemotherapy's International Congress of Chemotherapy and Infection (ICAAC/ICC 2015) scientific conference in San Diego, California, September 17-21, 2015.

21 Sep 2015

Evidera releases new software platform to support real-time analysis of healthcare data

Evidera, a leading provider of evidence-based solutions for the healthcare industry, is pleased to announce Evalytica, a new software platform designed to support near real-time analyses of virtually any type of real-world data source, including claims, electronic medical records, and registry data.

21 Sep 2015

Takeda Pharmaceutical's $2.37 billion settlement over Actos drug moves forward

MT Services LLC, a Lawsuit Settlement News Reporting Company which operates lawsuitsettlementnews.com, announced today that Takeda Pharmaceutical Co.'s $2.37 billion settlement over their diabetes drug Actos is going through and moving forward. Actos drug maker, Takeda, agreed to toss in another $100 million if enough claimants signed up with matching settlement criteria – 97% of the claims to be exact.

21 Sep 2015

Using deep learning to analyze genetic mutations: an interview with Brendan Frey

To understand deep learning in the context of genetic disease, you need to understand shallow learning first. Shallow learning relates mutations to diseases by looking for mutations that commonly occur in patients with a disease. It’s a commonly used method.

21 Sep 2015

Promising new innovations in drug development, health monitoring may improve drug safety in the future

Adverse drug reactions are harmful to patients and a major burden for healthcare providers, governments and the pharmaceutical industry. But promising new breakthroughs in drug development and health monitoring may enhance drug safety in the future, according to an editorial to be published in the next edition of the British Journal of Clinical Pharmacology.

21 Sep 2015

Novel nebuliser could one day deliver life-saving cancer drugs

A revolutionary nebuliser developed by RMIT University researchers could one day deliver life-saving cancer drugs and vaccines traditionally given by injection.

21 Sep 2015

BGB324 shows enhanced tumour clearance in mouse carcinoma models

BerGenBio AS, an oncology biopharmaceutical company, has announced new preclinical data on lead compound, BGB324, in combination with immune checkpoint inhibitors, has been presented as a poster at CRI-CIMT-EATI-AACR - The Inaugural International Cancer Immunotherapy Conference: Translating Science into Survival, in New York.

21 Sep 2015

Combination of TXA709 and cefdinir demonstrates synergistic antibacterial activity against MRSA

TAXIS Pharmaceuticals, a drug-discovery company focused on developing a new class of antibiotic agents to treat life-threatening, multidrug-resistant bacterial infections, announced the presentation of results demonstrating the synergistic antibacterial activity of its lead clinical candidate, TXA709, when combined with cefdinir, a third-generation cephalosporin antibiotic.

19 Sep 2015

Patient-oriented approach becomes a formula for long-term success in pharmaceutical industry

In the evolving global healthcare marketplace, a patient-centric approach has become part of the formula for long-term success in the pharmaceutical sector. Facing declining sales from patent losses and payer pressures, the pharma sector is turning to patient support programs and activities to help drive clinical and commercial success.

19 Sep 2015

Genetically engineered vaccine eradicates precancerous cervical lesions

Scientists have used a genetically engineered vaccine to successfully eradicate high-grade precancerous cervical lesions in nearly one-half of women who received the vaccine in a clinical trial. The goal, say the scientists, was to find nonsurgical ways to treat precancerous lesions caused by HPV.

18 Sep 2015

Pharmaceuticals News and Research

Johns Hopkins trained physicians create start-up to produce cheap generic drugs

OncoGenex reports results from Phase 2 Rainier study in patients with untreated metastatic pancreatic cancer

Novel graphene oxide-based biosensor may speed up development of new drugs against HIV, cancer

NJIT President Joel Bloom to be honored as Educator of the Year

Drug combination delivers effective punch against one form of pancreatic cancer

FDA approves LONSURF for treatment of patients with metastatic colorectal cancer

Type 2 diabetes risk grows with active and passive smoking

BWH, DFCI researchers receive $10 million to test effectiveness of aspirin in women with breast cancer

PDL BioPharma purchases portion of royalties on expected sales of AcelRx's Zalviso

Palatin Technologies reports net loss of $12.1 million for fourth quarter 2015

New Locilex microbiology data presented at ICAAC/ICC 2015 scientific conference

Evidera releases new software platform to support real-time analysis of healthcare data

Takeda Pharmaceutical's $2.37 billion settlement over Actos drug moves forward

Using deep learning to analyze genetic mutations: an interview with Brendan Frey

Promising new innovations in drug development, health monitoring may improve drug safety in the future

Novel nebuliser could one day deliver life-saving cancer drugs

BGB324 shows enhanced tumour clearance in mouse carcinoma models

Combination of TXA709 and cefdinir demonstrates synergistic antibacterial activity against MRSA

Patient-oriented approach becomes a formula for long-term success in pharmaceutical industry

Genetically engineered vaccine eradicates precancerous cervical lesions

Event guide: World ADC London eBook

Latest eBooks

Editorial Focus eBook - Spatial and single-cell omics (1st edition)

Industry Focus eBook - Analytical Chemistry (3rd edition)

Industry Focus eBook - Microbiome (1st edition)

Industry Focus eBook - Cell biology (5th edition)

Improving healthcare sustainability through carbon data

A New Approach to Preventing Bladder Cancer Recurrence

Bringing real-time analytics to downstream bioprocess monitoring